Cases of myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) have been registered after exposure to PARP inhibitors among patients with ovarian cancer and other solid tumors [67]. This evidence concerns the gene PARP1 and acute myeloid leukemia.